04 September 2010
Keywords: Nycomed, Third quarter 2009 results, Pantoprazole, Daxas
Article | 13 November 2009
Privately-owned Swiss prescription and over-the-counter drugmaker Nycomed reports continued satisfactory performance in the third quarter 2009, with total net turnover increasing 0.9% (3.2% in local currencies) to 820.0 million euros ($1.22 billion).
S
ales of its gastrointestinal drug pantoprazole were resilient after losing patent protection in May in 12 European countries, falling just 15.7% to 272.8 million euros. Moreover, the company noted, OTC variants of the drug were performing well in Europe. On a regional basis, group sales in most emerging markets exhibited strong growth. Adjusted EBITDA decreased 3.1% (1.5% in local currencies) to 285.3 million euros.
The firm said its pipeline portfolio had advanced significantly. Enjoying this article? To continue reading you need to login, take a FREE trial or subscribe.
FREE unlimited, no obligation access to The Pharma Letter website for 30 days, normally worth £60!
Sign up in less than 60 seconds...no payment needed
Take a no obligations 30 day trial.
Only one trial per user. Find out more details
Subscriptions are £60 per month, pay as you go.
Find out more details.